Benlysta will be lupus market leader in 2021 with sales of more than $1.7 ... The Pharma Letter The off-label use of two high-priced agents - the biologic rituximab (Biogen Idec/Roche/Chugai/Zenyaku Kogyo's Rituxan, Roche's MabThera) and the immunosuppressant mycophenolate mofetil (Roche/Galenica's CellCept, generics) -generated the majority ... |
